Navigation Links
OptiNose Completes Series C-1 Financing
Date:8/4/2014

YARDLEY, Pa., Aug. 4, 2014 /PRNewswire/ -- OptiNose, a specialty pharmaceutical company, announced today that it has completed a Series C-1 round of financing led by existing investors. Since obtaining Series C financing in 2010, OptiNose has successfully developed AVP-825, a product that, once approved, will be used for the treatment of migraines. OptiNose out-licensed the North American marketing rights for AVP-825 to a partner and jointly submitted a New Drug Application with the U.S. FDA earlier this year. In parallel with that program, OptiNose has actively pursued the significantly larger development program of OPN-375, a new product with applications in the treatment of serious chronic nasal inflammatory diseases.

Sriram Venkataraman, a director of OptiNose and a partner at Avista Capital Partners, said, "We are pleased with the progress of the clinical development programs to date and are committed to supporting the OptiNose team further as they execute on their clinical and commercial priorities, especially the development of the major new product OPN-375."

"With this latest round of financing, we are well-positioned to take the actions necessary to maximize the potential of our second product, OPN-375, which we believe will be a transformational breakthrough product in a large market with significant unmet need," said Peter Miller, Chief Executive Officer of OptiNose. "I am proud of the OptiNose team and the progress we have made together to date. I am also very excited about the future, as we continue late-phase clinical research, prepare commercial supply chain, and engage in pre-commercialization efforts around OPN-375."

About OPN-375

OPN-375 uses OptiNose's patented technology to deliver a highly effective and well-understood topical steroid medication (fluticasone) into the nasal cavity in a deeply distributed manner that improves u
'/>"/>

SOURCE OptiNose
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
2. OptiNose mottar stipend for nese-til-hjerne-forskning innen spektrumet for autismesykdommer
3. MGC Diagnostics Corporation Completes Acquisition of MediSoft SA
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytrens Contracture In Japan
5. Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427
6. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
7. TeraMedica Completes one of the Worlds Largest VNA Installations in New South Wales, Australia
8. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
9. Verus Healthcare Completes Over 85 Acquisitions
10. Virobay Completes $8 Million Series B Preferred Stock Financing
11. Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter , ... seem pre-wired to acquire a second language, new research suggests. ... will likely gain a brain boost, the small study finds. ... learning," said study co-author Ping Li, co-director of the Center ... it,s even more interesting, Li said, that "the brain networks ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... vaccine appears to be safe and produces an immune system ... to early clinical trial results reported by the U.S. National ... clinical trial for the vaccine paves the way for field-testing ... Sierra Leone as early as January, said Dr. Anthony Fauci, ...
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... 2014 Jeffrey Carlini has practiced ... Charlotte area providing audits, reviews, compilations, tax preparation, ... of varying size across numerous industries. Jeff has ... all of their accounting and tax needs. , ... ProAdvisor Program. When asking Mr. Carlini about his ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
... the length of time spent using mobile telephones has ... (RF) radiations.// It has been proposed that a precautionary ... at present, there is no convincing scientific data to ... ,In view of the proximity between radio-frequency source ...
... and resultant facial scarring. A new study in the ... the American Society for Dermatologic Surgery//, reports that patients ... showed significant improvement of mild to severe acne scars ... as facial resurfacing, dermabrasion and chemical peels. ...
... elbow has been enjoying the spot light following ace cricketer ... However, the condition is not uncommon in the sports arena//. ... called in medical parlance, is an affliction where the outer ... a result of a specific strain, overuse or a direct ...
... blood pressure (BP) increase is one of the most ... most patients the condition, although urgent, is not an ... no guidelines on how to treat patients with acute ... cause of excessive hypertension and therefore antianxiety treatment may ...
... Researchers from Children’s Hospital of Boston have reconstructed ... The researchers used amniotic fluid for growing the ... these living tissues into lambs, while they were ... is used for altering birth defects. Undifferentiated stem ...
... yeast strains might have spawned an outbreak of disease ... British Columbia, Howard Hughes Medical Institute geneticists at Duke ... is normally restricted to the tropics and subtropics. ... in the pathogen's expansion may provide a useful model ...
Cached Medicine News:Health News:Mobile phones may influence normal brain functioning 2Health News:Tennis elbow not new among cricketers, say experts 2Health News:Anti-anxiety treatment found effective in lowering blood pressure 2Health News:Sex Played A Vital Role For Evolution Of Infectious Diseases 2
... HypercleanTM 22 fume containment system ... a one- or two-person work ... containment system comes complete ... four charcoal filters. (For replacement ...
Surgical-grade stainless steel disposable concentric needle with Trocar tip has an insulated platinum-alloy core and two attached 61-cm (24-in) lead wires. Needles sold in packages of 20....
... Rotavirus is the most common ... for 5% of pediatric visits ... children under 5 years. ImmunoSTAT! ... to rule in or rule ...
... test delivers 100% specificity and 100% ... minutes. With as many as ... follow-up, this assay provides a test ... to detection and treatment while reducing ...
Medicine Products: